Impact of Intraoperative Magnetic Resonance Imaging on Gross Total Resection, Extent of Resection, and Residual Tumor Volume in Pituitary Surgery: Systematic Review and Meta-analysis
Overview
Affiliations
Background: Residual tumor tissue after pituitary adenoma surgery, is linked with additional morbidity and mortality. Intraoperative magnetic resonance imaging (ioMRI) could improve resection. We aim to assess the improvement in gross total resection (GTR), extent of resection (EOR), and residual tumor volume (RV) achieved using ioMRI.
Methods: A systematic review was carried out on PubMed/MEDLINE to identify any studies reporting intra- and postoperative (1) GTR, (2) EOR, or (3) RV in patients who underwent resection of pituitary adenomas with ioMRI. Random effects meta-analysis of the rate of improvement after ioMRI for these three surgical outcomes was intended.
Results: Among 34 included studies (2130 patients), the proportion of patients with conversion to GTR (∆GTR) after ioMRI was 0.19 (95% CI 0.15-0.23). Mean ∆EOR was + 9.07% after ioMRI. Mean ∆RV was 0.784 cm. For endoscopically treated patients, ∆GTR was 0.17 (95% CI 0.09-0.25), while microscopic ∆GTR was 0.19 (95% CI 0.15-0.23). Low-field ioMRI studies demonstrated a ∆GTR of 0.19 (95% CI 0.11-0.28), while high-field and ultra-high-field ioMRI demonstrated a ∆GTR of 0.19 (95% CI 0.15-0.24) and 0.20 (95% CI 0.13-0.28), respectively.
Conclusions: Our meta-analysis demonstrates that around one fifth of patients undergoing pituitary adenoma resection convert from non-GTR to GTR after the use of ioMRI. EOR and RV can also be improved to a certain extent using ioMRI. Endoscopic versus microscopic technique or field strength does not appear to alter the impact of ioMRI. Statistical heterogeneity was high, indicating that the improvement in surgical results due to ioMRI varies considerably by center.
Glancz L, Hannan C, Vyziotis A, Potter G, Siripurapu R, Bhalla R BMJ Oncol. 2025; 3(1):e000386.
PMID: 39886144 PMC: 11347697. DOI: 10.1136/bmjonc-2024-000386.
Hannan C, Daousi C, Radon M, Gilkes C Oper Neurosurg (Hagerstown). 2024; 28(4):487-495.
PMID: 39162407 PMC: 11893087. DOI: 10.1227/ons.0000000000001319.
Huang Y, Qin L, Lv H, Lv S, Lu Y Quant Imaging Med Surg. 2024; 14(7):5012-5027.
PMID: 39022256 PMC: 11250324. DOI: 10.21037/qims-23-1570.
Intraoperative magnetic resonance imaging in glioma surgery: a single-center experience.
Mirzayeva L, Ucar M, Kaymaz A, Temel E J Neurooncol. 2024; 168(2):249-257.
PMID: 38568377 PMC: 11147832. DOI: 10.1007/s11060-024-04660-z.
Korbonits M, Blair J, Boguslawska A, Ayuk J, Davies J, Druce M Nat Rev Endocrinol. 2024; 20(5):278-289.
PMID: 38336897 DOI: 10.1038/s41574-023-00948-8.